Serum Irisin Levels and Clinical Implication in Elderly Patients With Type 2 Diabetes Mellitus

Abstract

Background The aim of this study is to evaluate the level and role of serum irisin in elderly patients with type 2 diabetes mellitus (T2DM) using case-control study. Methods A total of 71 patients with T2DM were selected as the case group according to the inclusion criteria and exclusion criteria; and the ratio of 1:1 was calculated according to the inclusion rate of the residents. The cohort established in Guankou Town, Jimei District, Xiamen City, Fujian Province, China and the residents of this cohort were selected at the age of 60 and above. A total of 71 healthy subjects were included as the control group with the same gender and the age with a difference of ± 5 years old. The clinical data of the subjects were collected to determine their previous history, blood pressure, body mass index (BMI), hemoglobin (HB), liver function test, renal function test, fasting blood glucose and serum lipid. The irisin level in serum was measured by enzyme-linked immunosorbent assay (ELISA). The data were analyzed by using SPSS17.0 software. Single factor analysis using Chi-square test or t -test was performed to compare the differences between T2DM patients with the control group of the general data, clinical indicators and irisin level in serum. Logistic regression was used to analyze the protective factors and risk factors of diabetes mellitus. Results The results of single factor analysis showed that the level of irisin in T2DM group was significantly lower than that in the control group (703.37 ± 241.51 ng/mL and 800.22 ± 275.59 ng/mL, respectively). The levels of BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), triglyceride (TG) and fasting plasma glucose (FPG) in T2DM group were higher than those in control group, and differences were statistically significant. Logistic regression analysis indicated that irisin may be a protective factor for type 2 diabetes (odds ratio (OR) = 0.997, 95% confidence interval (CI): 0.994 - 0.999). Conclusions The serum irisin level in T2DM group was significantly lower than that in control group, suggesting that irisin may be a protective factor for type 2 diabetes.

Evaluation of serum adropin and irisin levels and its association with anthropometric obesity indices and biochemical parameters in Type 2 diabetic patients

“…Irisin levels can provide new avenues for controlling age-related muscle changes since it's a potential biomarker for muscle dysfunction that could portend the onset of sarcopenia [19]. Irisin levels were studied in elderly patients with diabetes it was lower than the control group of healthy subjects with the same gender characteristics and age with a difference of ± 5 years old [20]. On the other hand, serum adropin concentrations are negatively associated with renal function.…”

Intermittent fasting and exercise therapy abates STZ‐induced diabetotoxicity in rats through modulation of adipocytokines hormone, oxidative glucose metabolic, and glycolytic pathway

“…Irisin, a new adipocytokine, is released, activated, and transported to a variety of tissues and organs to carry out its physiological tasks. It can, for example, improve insulin resistance, boost uncoupling protein‐1 expression, convert white fat into brown fat with catabolic properties, increase energy consumption and glucose utilization, and coordinate the treatment of metabolic illnesses like obesity and type 2 diabetes (Jung et al, 2017 ; Rizk et al, 2016 ; Xuan et al, 2020 ).…”

The Physiological Role of Irisin in the Regulation of Muscle Glucose Homeostasis

“…A list of the animal and human study papers to note is summarized in Table 1 [16,20,34,37,50,54,70,[134][135][136]138,139,[141][142][143][144][145].…”

“…María et al proposed that in individuals with obesity, FNDC5 expression in muscle was significantly decreased in association with T2DM, and FNDC5 expression in muscle was significantly associated with FNDC5 and UCP1 expression in visceral adipose tissue [ 133 ]. In most clinical studies, irisin levels of patients with pre-diabetes or T2DM have been reported to be lower than the controls [ 134 , 138 , 139 ]. The factor that is responsible for the low secretion of irisin in T2DM has not yet been identified, although some studies have suggested that chronic hyperglycemia and hyperlipidemia are possible causes [ 37 , 70 ].…”